Insulet Corporation (PODD)
| Market Cap | 9.23B -54.6% |
| Revenue (ttm) | 3.05B +29.4% |
| Net Income | 375.30M +59.0% |
| EPS | 5.30 +60.1% |
| Shares Out | 69.26M |
| PE Ratio | 25.16 |
| Forward PE | 19.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,177,705 |
| Open | 128.00 |
| Previous Close | 166.82 |
| Day's Range | 126.40 - 138.41 |
| 52-Week Range | 126.40 - 354.88 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 197.68 (+48.34%) |
| Earnings Date | Aug 5, 2026 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for PODD stock is "Buy." The 12-month stock price target is $197.68, which is an increase of 48.34% from the latest price.
News
Insulet downgraded to Market Perform from Outperform at Leerink
Leerink analyst Mike Kratky downgraded Insulet (PODD) to Market Perform from Outperform with a $145 price target
Insulet price target lowered to $160 from $245 at RBC Capital
RBC Capital lowered the firm’s price target on Insulet (PODD) to $160 from $245 and keeps an Outperform rating on the shares. Insulet lowered its FY26 Omnipod growth outlook due…
Insulet price target lowered to $179 from $249 at Canaccord
Canaccord lowered the firm’s price target on Insulet (PODD) to $179 from $249 and keeps a Buy rating on the shares. The firm said Insulet delivered a Q2 revenue and…
Insulet downgraded to Neutral from Buy at BTIG
BTIG analyst Marie Thibault downgraded Insulet (PODD) to Neutral from Buy without a price target The company beat Q2 estimates but called out lower utilization and retention trends in the…
Insulet downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Insulet (PODD) to Neutral from Overweight with a price target of $152, down from $275. JPMorgan also removed the shares from its Analyst Focus List. Insulet’s slower new…
Insulet downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Larry Biegelsen downgraded Insulet (PODD) to Equal Weight from Overweight with a price target of $144, down from $255, following the Q2 report. The company cut its…
Insulet downgraded to Hold from Buy at Truist
Truist downgraded Insulet (PODD) to Hold from Buy with a price target of $153, down from $210. The firm sees the company’s churn in type 2 diabetes and “soon-to-be intensifying”…
Oppenheimer calls Insulet outlook ‘huge surprise,’ downgrades shares
Oppenheimer downgraded Insulet (PODD) to Perform from Outperform without a price target following the Q2 report. Insulet lowered its fiscal 2026 U.S. growth to 17%-19% and its implied 2027 outlook…
Insulet downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Suraj Kalia downgraded Insulet (PODD) to Perform from Outperform.
Insulet price target lowered to $150 from $172 at Citi
Citi lowered the firm’s price target on Insulet (PODD) to $150 from $172 and keeps a Neutral rating on the shares post the Q2 report. The firm says the company’s…
This Medtech Beat Earnings Estimates. It's the Worst S&P 500 Stock Today.
Insulet lowers its full-year revenue growth outlook, even after earnings and revenue handily beat expectations.
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall
Insulet lowered its annual sales growth forecast on Wednesday, pointing to a softer second half of 2026 particularly for U.S. sales of its Omnipod insulin pumps, sending shares of the company down m...
Insulet Earnings Call Transcript: Q2 2026
Q2 saw 23% revenue growth, margin expansion, and strong EPS, driven by robust demand and international momentum. Lower retention among Type 2 customers led to revised guidance, with new initiatives underway to improve onboarding and support. Long-term growth prospects remain strong.
Insulet Earnings release: Q2 2026
Insulet released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Insulet Slides: Q2 2026
Insulet has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Insulet Quarterly report: Q2 2026
Insulet has published its Q2 2026 quarterly earnings report on August 5, 2026.
Insulet raises FY26 adjusted EPS growth view to at least 30% from at least 25%
Cuts FY26 Drug Delivery Total Growth to 20%-22% from 21%-23%
Insulet reports Q2 EPS $1.66, consensus $1.45
Reports Q2 revenue $801.7M, consensus $787.43M. “We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow, reflecting the strength of the Omnipod platfo...
Insulet Reports Second Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
PODD INVESTOR REMINDER: Insulet Corporation Investors Have Until August 31, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)---- $PODD #classaction--If you have suffered a loss on your Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investment, contact Lauren Molinaro of Kirby McIne...
Insulet assumed with Neutral from Buy at UBS
UBS downgraded Insulet (PODD) to Neutral from Buy with a price target of $174, down from $400, after assuming coverage of the name, as part of a broader note on…
Insulet assumed with Neutral from Buy at UBS
UBS downgraded Insulet (PODD) to Neutral from Buy with a $174 price target after assuming coverage of the name.